

November 11, 2019

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, November 11, 2019

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board meeting of the Company held on Monday, November 11, 2019 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2019. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated November 11, 2019 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited



Pratap Rudra
Company Secretary & Legal Counsel



CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of unaudited financial results for the quarter and six months ended 30 September 2019

Sl No.	Particulars	Rs in lakhs except for earnings per share data					
		3 months ended 30/09/2019	Previous 3 months ended 30/06/2019	Corresponding 3 months ended in the previous year 30/09/2018	6 months ended 30/09/2019	6 months ended 30/09/2018	Year ended 31/03/2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	Audited
1	Revenue						
	a) Revenue from operations	20,848.31	20,456.13	16,136.08	41,304.44	32,279.76	72,829.43
	b) Other income	316.08	298.92	335.45	614.99	677.73	1,628.52
	Total income	21,164.39	20,755.05	16,471.53	41,919.43	32,957.49	74,457.95
2	Expenses						
	(a) Cost of materials consumed	1,328.21	1,875.47	856.25	3,203.69	2,449.23	6,267.23
	(b) Purchase of stock-in-trade	6,358.21	4,667.63	2,736.24	11,025.84	4,735.69	16,983.88
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(270.94)	460.81	1,590.00	189.87	3,238.04	(137.78)
	(e) Employee benefits expense	5,216.35	5,073.41	4,398.04	10,289.76	8,589.93	19,739.86
	(f) Depreciation and amortisation expense	464.06	462.74	367.38	926.79	722.42	1,492.41
	(g) Selling, marketing and distribution expense	1,401.17	1,698.33	1,168.43	3,099.50	4,030.45	7,980.28
	(h) Other expenses	3,459.35	3,124.21	3,910.81	6,583.56	6,832.16	14,865.72
	(i) Finance cost	28.36	29.54	-	57.90	-	-
	Total expenses	17,984.77	17,392.14	15,027.15	35,376.91	30,597.92	67,191.60
3	Profit before exceptional and extraordinary items and tax (1-2)	3,179.62	3,362.91	1,444.38	6,542.52	2,359.57	7,266.35
4	Exceptional items	-	-	-	-	-	-
5	Profit before extraordinary items and tax (3+4)	3,179.62	3,362.91	1,444.38	6,542.52	2,359.57	7,266.35
6	Extraordinary items	-	-	-	-	-	-
7	Profit before tax (5+6)	3,179.62	3,362.91	1,444.38	6,542.52	2,359.57	7,266.35
8	Tax expense (refer Note 3)						
	- Current tax	514.68	1,269.53	437.87	1,784.21	701.34	1,667.83
	- Deferred tax	1,223.41	(58.16)	93.35	1,165.25	105.73	154.45
	Total tax expense	1,738.09	1,211.37	531.22	2,949.46	807.07	1,822.28
9	Profit for the period (7-8)	1,441.53	2,151.54	913.16	3,593.06	1,552.50	5,444.07
10	Other comprehensive income						
	A. Items that will not be reclassified to profit or loss						
	Re-measurement gains/(losses) on post employment benefit obligations	(114.85)	(344.04)	(56.29)	(458.90)	199.65	(92.30)
	Income tax effect on above	(4.73)	120.22	19.67	115.50	(69.77)	32.25
	Total other comprehensive income/ (loss), net of income tax	(119.58)	(223.82)	(36.62)	(343.40)	129.88	(60.05)
	Total comprehensive income for the period (9+10)	1,321.95	1,927.72	876.54	3,249.66	1,682.38	5,384.02
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00	500.00	500.00
12	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-	-	-	29,580.50
13	Earnings per equity share of Rs 2/- each (basic and diluted)	5.77	8.61	3.65	14.37	6.21	21.78



Jagan

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 Effective 1 April 2019, the Company has adopted Ind AS 116, 'Leases'. Ind AS 116 introduces a single lessee accounting model and requires a lessee to recognise right-of-use assets and lease liabilities for all leases with a term of more than twelve months, unless the underlying asset is of a low value.

The Company has used the 'modified retrospective approach' for transition from Ind AS 17, 'Leases', and consequently, comparatives for previous periods have not been adjusted. On transition, the Company has recorded lease liability at present value of future lease payments discounted using the incremental borrowing rate and has recognised the right-of-use asset at an amount equal to the lease liability and adjusted for prepaid lease payments.


The adoption of Ind AS 116 has resulted in recognition of right-of-use assets of Rs.1,211.30 lakhs under Property, plant and equipment and lease liabilities of Rs.1,224.41 lakhs under Other financial liabilities (Rs. 989.84 lakhs classified as non-current and Rs. 234.57 lakhs classified as current) with a corresponding effect of Rs.12.98 lakhs on retained earnings on 1 April 2019.

In the financial results for the quarter and half year ended 30 September 2019, the nature of expense for leasing arrangements has changed from lease rent in previous periods to depreciation on the right-of-use assets and finance cost on the corresponding lease liabilities. The adoption of Ind AS 116 did not have a material impact on the results for the quarter and half year ended 30 September 2019.
- 3 Pursuant to a notification of the Taxation Laws (Amendment) Ordinance 2019, the Company has opted to pay tax as per Section 115BAA at the income tax rate of 22% (plus applicable surcharge and cess). Consequently, during the quarter ended 30 September 2019, the Company has recognised the impact of remeasurement of the net deferred tax assets and the current tax charge.
Accordingly, the excess current tax provision relating to quarter ended 30 June 2019 amounting to Rs. 353.62 lakhs has been reversed in the Unaudited Statements of Financial Results in the quarter ended 30 September 2019.
Similarly, the excess net deferred tax assets (including minimum alternate tax) of Rs. 1,246.56 lakhs have been reversed in the Unaudited Statements of Financial Results in the quarter ended 30 September 2019.
- 4 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 5 As previously disclosed, by way of a letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 6 The comparative figures for cash flows for the six months ended 30 September 2018 included in the Unaudited Statements of Cash flows have been prepared by Management, reviewed by the Audit Committee and approved by the Company's Board of Directors at their respective meetings held on 11 November 2019, but have not been subjected to review by the statutory auditors as the mandatory requirement for limited review of cash flows has been made applicable for periods beginning 1 April 2019, pursuant to Regulation 33(8) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 7 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 8 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 11 November 2019. The Statutory Auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 September 2019.

Place: Mumbai
Date: 11 November, 2019



By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Gagandeep Singh Bedi
Managing Director

AstraZeneca Pharma India Limited

Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Unaudited Statement of assets and liabilities as at 30 September 2019

SI.No.	Balance Sheet	(Rs in lakhs)	
		As at 30 September 2019 (Unaudited)	As at 31 March 2019 (Audited)
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	7,985.08	7,483.05
	(b) Capital work-in-progress	1,665.30	690.06
	(c) Financial Assets		
	(i) Loans	402.54	286.03
	(d) Current tax assets	4,643.87	4,644.17
	(e) Deferred tax assets	1,273.17	2,336.92
	(f) Other non-current assets	186.34	269.05
	Sub-total - Non-current assets	16,156.30	15,709.28
2	Current assets		
	(a) Inventories	12,560.00	11,810.74
	(b) Financial Assets		
	(i) Trade receivables	9,202.37	7,975.00
	(ii) Cash and cash equivalents	23,116.72	17,324.00
	(iii) Bank balances other than (ii) above	1.77	5.71
	(iv) Loans	88.89	81.08
	(v) Other financial current assets	1,124.00	555.63
	(c) Other current assets	2,360.14	2,720.09
	Sub-total - Current assets	48,453.89	40,472.25
	TOTAL - ASSETS	64,610.19	56,181.53
1	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	500.00	500.00
	(b) Other Equity	32,458.27	29,580.50
	Sub-total - Shareholders' funds	32,958.27	30,080.50
	LIABILITIES		
	Non-current liabilities		
	(a) Provisions	1,706.79	202.10
	Sub-total - Non-current liabilities	1,706.79	202.10
2	Current liabilities		
	(a) Financial Liabilities		
	(i) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	14.95	45.20
	Total outstanding dues of creditors other than micro enterprises and small enterprises	20,105.90	16,775.12
	(ii) Other financial liabilities	3,974.58	4,000.10
	(b) Other current liabilities	1,187.64	988.27
	(c) Provisions	4,187.31	3,907.06
	(d) Current tax liability	474.75	183.18
	Sub-total - Current liabilities	29,945.13	25,898.93
	TOTAL - EQUITY AND LIABILITIES	64,610.19	56,181.53



AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli,
Outer Ring Road, Bangalore 560 045

Unaudited Statement of Cash Flows for six months ended September 30, 2019

(Rs in Lakhs)

Particulars	Six months ended September 30, 2019	Six months ended September 30, 2018
	(Unaudited)	(refer Note 6)
Cash flows from Operating activities		
Profit Before Tax	6,542.52	2,359.57
Non Cash Adjustments for:		
Depreciation expense	926.79	722.42
Profit on sale of Property, Plant and Equipment	(10.87)	(6.16)
Interest on financial assets carried at amortised cost	(595.63)	(486.75)
Employee stock compensation expense	54.11	52.17
Expected Credit Losses	50.46	196.75
Provision for doubtful advances	-	13.80
Unrealised foreign exchange (gains)/losses, (net)	13.70	(56.32)
Interest cost on lease liabilities	57.90	-
Operating profit before working capital changes	7,038.99	2,795.48
Changes in Working Capital:		
(Increase) / Decrease in trade receivables	(1,294.79)	(742.13)
(Increase) / Decrease in inventories	(748.77)	3,429.63
(Increase) / Decrease in loans	(125.32)	11.32
(Increase) / Decrease in other financial assets	(551.11)	(582.00)
(Increase) / Decrease in other assets	347.77	416.81
Increase / (Decrease) in trade payables	3,303.50	2,265.99
Increase / (Decrease) in provisions	336.21	(1,009.67)
Increase / (Decrease) in other financial liabilities	(183.17)	(254.12)
Increase / (Decrease) in other liabilities	(35.20)	116.44
Cash Generated from Operations	8,088.11	6,447.75
Income taxes paid (net of refunds)	(1,492.64)	3.15
Net cash generated from operating activities (A)	6,595.47	6,450.90
Cash Flows from Investing activities		
Purchase of Property, Plant and Equipment	(933.89)	(743.05)
Proceeds from sale of Property, Plant and Equipment	18.01	13.37
Interest Income on bank deposits	578.37	456.66
Proceeds from maturities of bank deposits	-	1,168.26
Net cash generated from / (used in) investing activities (B)	(337.51)	895.24
Cash flows from Financing activities		
Principal repayment on lease liabilities	(105.94)	-
Interest payment on lease liabilities	(57.90)	-
Dividends paid	(250.00)	-
Tax on dividend payment	(51.40)	-
Net cash generated from / (used in) financing activities (C)	(465.24)	-
Net increase/(decrease) in cash and cash equivalents (D=A+B+C)	5,792.72	7,346.14
Cash and Cash equivalents at the beginning of the period (E)	17,324.00	11,398.24
Cash and Cash equivalents at the end of the period (D+E)	23,116.72	18,744.38



Price Waterhouse & Co Chartered Accountants LLP

To
The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bengaluru- 560045

Independent Auditor's Report on the Statement of financial results

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter and the half year ended September 30, 2019 which are included in the accompanying 'Statement of unaudited financial results for the quarter and six months ended 30 September 2019', 'Statement of Assets and Liabilities' as on that date and the 'Statement of cash flows' for the half-year ended on that date (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We were neither engaged to review, nor have we reviewed the comparative figures for the statement of cash flows for the period April 1, 2018 to September 30, 2018 and accordingly, we do not express any conclusion on the cash flows presented in the accompanying Statement for the period from April 1, 2018 to September 30, 2018. As set out in note 6 to the Statement, these figures have been furnished by the Management. Our conclusion on the Statement is not modified in respect of this matter.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009



Pradip Kanakia
Partner

Membership Number: 039985
UDIN: 19039985AAAACD3522

Bengaluru
Date: November 11, 2019

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road
Ulsoor, Bangalore-560 008
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP Identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)